Moreover, we found that the NEAT1 and MALAT1 expression was decreased by the T2DM group treated with metformin (T2DM+met, 300 mg/kg) for eight weeks; the T2DM group was administered SBU (T2DM+SBU, 300 mg/mL) for eight weeks (Figure 5a,b). The gene discussed is MALAT1; the disease is type 2 diabetes mellitus.